Weight Management
Triple Receptor Agonist · Research Use Only
Retatrutide is an advanced next-generation peptide that simultaneously activates three key metabolic receptors — GLP-1, GIP, and Glucagon — offering a comprehensive approach to metabolic health, body composition, and weight management.
How It Works
Retatrutide represents the cutting edge of metabolic peptide research. Unlike earlier generation GLP-1 agonists, Retatrutide simultaneously engages three distinct receptor pathways, creating a synergistic effect on metabolic regulation that is unmatched by single or dual-receptor approaches.
"The most advanced metabolic peptide in research — activating three pathways simultaneously for comprehensive metabolic support."
By targeting GLP-1, GIP, and Glucagon receptors in concert, Retatrutide addresses multiple dimensions of metabolic function — from appetite regulation and insulin sensitivity to energy expenditure and lipid metabolism.
GLP-1 Receptor Agonism
Glucagon-like peptide-1 receptor activation supports appetite regulation, promotes satiety signaling, and helps modulate blood glucose levels by stimulating insulin secretion in a glucose-dependent manner.
GIP Receptor Agonism
Glucose-dependent insulinotropic polypeptide receptor activation enhances insulin sensitivity, supports fat metabolism, and works synergistically with GLP-1 to amplify metabolic benefits beyond what either receptor achieves alone.
Glucagon Receptor Agonism
Glucagon receptor activation increases energy expenditure, promotes hepatic fat oxidation, and supports thermogenesis — adding a powerful third dimension to metabolic support that distinguishes Retatrutide from dual-agonist peptides.
Research Highlights
Based on emerging research, Retatrutide demonstrates a broad spectrum of metabolic effects across multiple physiological systems.
Research suggests Retatrutide may support significant improvements in body composition, including reductions in adipose tissue and preservation of lean muscle mass — outcomes that exceed those observed with single-receptor agonists.
The glucagon receptor component of Retatrutide's triple-agonist profile may increase basal metabolic rate and thermogenesis, supporting greater energy expenditure compared to GLP-1 or dual GLP-1/GIP approaches alone.
Combined GLP-1 and GIP receptor activation supports robust glucose-dependent insulin secretion and improved insulin sensitivity, contributing to more stable blood glucose profiles in research models.
Emerging research indicates potential improvements in cardiovascular risk markers, including lipid profiles and inflammatory biomarkers, associated with the comprehensive metabolic effects of triple-receptor agonism.
GLP-1 receptor activation in the central nervous system supports appetite suppression and enhanced satiety signaling, contributing to reduced caloric intake in research subjects.
Glucagon receptor agonism promotes hepatic fat oxidation, with research suggesting potential benefits for non-alcoholic fatty liver disease (NAFLD) markers and overall liver health metrics.
Product Details
Every ÜAJIRA Wellness product meets the highest standards of purity and quality for research applications.
| Product Name | Retatrutide |
| Classification | Triple GLP-1 / GIP / Glucagon Receptor Agonist |
| Molecular Weight | ~4.8 kDa |
| Sequence Origin | Synthetic peptide analogue |
| Purity | ≥98% (HPLC verified) |
| Form | Lyophilized powder |
| Storage | Refrigerate at 2–8°C. Protect from light. |
| Stability | 24 months lyophilized; 30 days reconstituted |
| Category | Weight Management |
| Intended Use | Research Use Only. Not for human consumption. |
| Pricing | From $108.90 — Contact us to inquire |
Also in Weight Management
Explore our complete weight management collection, each formulated for precision metabolic support.
Exclusive Access
Connect with others focused on health, longevity, fitness, recovery, and personal wellness. Get exclusive access to new products, expert insights, and members-only wellness protocols.
